Peptide therapeutics in the management of metastatic cancers. Issue 33 (2nd August 2022)

• Record Type: Journal Article
• Authors: Bose, Debopriya; Roy, Laboni; Chatterjee, Subhrangsu
• Is Part Of: RSC advances. Volume 12:Issue 33(2022)
• Page Start: 21353
• Page End: 21373
• Publication Date: 2022-08-02
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d2ra02062a
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : The arsenal of anti-cancer medicinal peptides: modes of action. Abstract : Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed various modes in which peptides are being used to curb cancer. Our review highlights specially the various anti-metastatic peptide-based agents developed by targeting a plethora of cellular factors. Herein we have given a special focus on integrins as targets for peptide drugs, as these molecules play key roles in metastatic progression. The review also discusses use of peptides as anti-cancer vaccines and their efficiency as drug-delivery tools. We hope this work will give the reader a clear idea of the mechanisms of peptide-based anti-cancer therapeutics and encourage the development of superior drugs in the future.